Login to Your Account

In the clinic

Friday, November 10, 2017

Anthera Pharmaceuticals Inc., of Hayward, Calif., completed patient recruitment for its phase III RESULT trial testing Sollpura in patients with exocrine pancreatic insufficiency caused by cystic fibrosis. Results of an interim futility analysis are expected in December and top-line data should be available in the first quarter of 2018.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription